Literature DB >> 23205106

Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling.

Yuki Katayama1, Moegi Maeda, Ken Miyaguchi, Shota Nemoto, Mahmut Yasen, Shinji Tanaka, Hiroshi Mizushima, Yutaka Fukuoka, Shigeki Arii, Hiroshi Tanaka.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the liver. Since postoperative recurrence and intrahepatic metastases occur frequently, the postoperative 5-year survival rate is low. To investigate the molecular mechanisms of HCC progression, mRNA as well as microRNA (miRNA) expression levels have been profiled in various studies. However, no previous study has comprehensively compared the expression of miRNAs in HCC patients with various clinical features using the tumor and surrounding non-tumor tissues and normal liver samples. In this study, we profiled the expression of miRNAs in tumor and non-tumor tissues from 40 HCC patients with heterogeneous pathogenesis and 6 surrounding non-tumor tissues from patients with metastatic liver cancer. To identify miRNAs specific to each disease state, we comprehensively compared the expression of miRNAs in various combinations. The results indicate that the expression of many known as well as novel miRNAs was altered in patients with the hepatitis C virus infection compared with those with the hepatitis B virus and without any virus infection. The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.

Entities:  

Year:  2012        PMID: 23205106      PMCID: PMC3506695          DOI: 10.3892/ol.2012.810

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  59 in total

1.  HBV + HCV = HCC?

Authors:  M E Cramp
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 2.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).

Authors:  Daniëlle Bodmer; Marc Eleveld; Ellen Kater-Baats; Irene Janssen; Bert Janssen; Marian Weterman; Eric Schoenmakers; Michael Nickerson; Marston Linehan; Berton Zbar; Ad Geurts van Kessel
Journal:  Hum Mol Genet       Date:  2002-03-15       Impact factor: 6.150

4.  Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.

Authors:  Shunsuke Ura; Masao Honda; Taro Yamashita; Teruyuki Ueda; Hajime Takatori; Ryuhei Nishino; Hajime Sunakozaka; Yoshio Sakai; Katsuhisa Horimoto; Shuichi Kaneko
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

5.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas.

Authors:  Jiri Zavadil; Huihui Ye; Zhaojian Liu; JingJing Wu; Peng Lee; Eva Hernando; Patricia Soteropoulos; Gokce A Toruner; Jian-Jun Wei
Journal:  PLoS One       Date:  2010-08-24       Impact factor: 3.240

7.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Deregulated expression of miR-106a predicts survival in human colon cancer patients.

Authors:  Raquel Díaz; Javier Silva; José M García; Yolanda Lorenzo; Vanesa García; Cristina Peña; Rufo Rodríguez; Concepción Muñoz; Fernando García; Félix Bonilla; Gemma Domínguez
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

9.  MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.

Authors:  M Crawford; E Brawner; K Batte; L Yu; M G Hunter; G A Otterson; G Nuovo; C B Marsh; S P Nana-Sinkam
Journal:  Biochem Biophys Res Commun       Date:  2008-07-03       Impact factor: 3.575

10.  Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.

Authors:  Lingeng Lu; Dionyssios Katsaros; Irene A Rigault de la Longrais; Olga Sochirca; Herbert Yu
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

View more
  31 in total

1.  MicroRNA miR-1249 downregulates adenomatous polyposis coli 2 expression and promotes glioma cells proliferation.

Authors:  Baojun Fang; Guoliang Li; Chongfu Xu; Yuzuo Hui; Gang Li
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

2.  Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.

Authors:  Dongju Chen; Lei Liu; Xuegang Luo; Ai Mu; Lihua Yan; Xiaoying Chen; Lei Wang; Nan Wang; Hongpeng He; Hao Zhou; Tongcun Zhang
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

Review 3.  Role of circulatory microRNAs in the pathogenesis of hepatitis C virus.

Authors:  Iqra Almas; Samia Afzal; Muhammad Idrees; Muhammad Usman Ashraf; Iram Amin; Muhammad Shahid; Khadija Zahid; Sadia Zahid
Journal:  Virusdisease       Date:  2017-11-27

4.  MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection.

Authors:  Er-Lei Zhang; Jin Gu; Zun-Yi Zhang; Ke-Shuai Dong; Bin-Yong Liang; Zhi-Yong Huang
Journal:  Oncol Lett       Date:  2017-05-16       Impact factor: 2.967

5.  Differential MicroRibonucleic Acid Expression in Cardioembolic Stroke.

Authors:  Janhavi M Modak; Meaghan Roy-O'Reilly; Liang Zhu; Ilene Staff; Louise D McCullough
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-10-11       Impact factor: 2.136

6.  miR-581-Related Single Nucleotide Polymorphism, rs2641726, Located in MUC4 Gene, is Associated with Gastric Cancer Incidence.

Authors:  Fariba Nabatchian; Mahdis Rahimi Naiini; Afshin Moradi; Hossein Tabatabaeian; Negin Hoghoughi; Mansoureh Azadeh; Kamran Ghaedi
Journal:  Indian J Clin Biochem       Date:  2018-04-10

7.  miR-448 downregulates MPPED2 to promote cancer proliferation and inhibit apoptosis in oral squamous cell carcinoma.

Authors:  Linhan Shen; Liu Liu; Liangyu Ge; Long Xie; Siyu Liu; Lei Sang; Tiantian Zhan; Hongwei Li
Journal:  Exp Ther Med       Date:  2016-09-05       Impact factor: 2.447

8.  miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.

Authors:  Suna Zhou; Wenguang Ye; Yanjun Zhang; Dequan Yu; Qiuju Shao; Jun Liang; Mingxin Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

9.  NEDD 4 binding protein 2-like 1 promotes cancer cell invasion in oral squamous cell carcinoma.

Authors:  Tomonori Sasahira; Miyako Kurihara; Yukiko Nishiguchi; Rina Fujiwara; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  Virchows Arch       Date:  2016-05-16       Impact factor: 4.064

10.  miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3.

Authors:  Tingjia Cao; Hanjun Li; Yilin Hu; Dandan Ma; Xun Cai
Journal:  Tumour Biol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.